Pharmaceutical Executive Online Read the Full Article >> An estimated 64 million people suffer from heart failure (HF) globally. Americans have a 20% lifetime risk of developing HF. Although recent progress in the development of new treatments has led to a modest decrease in morbidity and mortality, mortality for heart failure patients remains unacceptably high[…]
Inside Precision Medicine Online Published: February 16, 2022 Read the Full Article >> Personalizing medicine using population-level insights can seem like a contradiction. On one hand, the goal is to better fit treatment to the individual patient, moving away from generalized approaches toward a “one size fits all” model. On the other, we have[…]
December 20, 2021 – Orphanet Journal of Rare Diseases Read the Full Article >> Background Fabry disease (FD) is a rare genetic disorder characterized by glycosphingolipid accumulation and progressive damage across multiple organ systems. Due to its heterogeneous presentation, the condition is likely significantly underdiagnosed. Several approaches, including provider education efforts and newborn screening, have[…]
Wed, Nov 17, 2021 11:00 AM – 12:00 PM EST Presenter: Dr. Joseph Zabinski, Senior Director of Data Solutions, OM1 Register >> Artificial Intelligence (AI) technology is increasingly being used for accelerating and optimizing clinical development. Yet, understanding useful implementation and its real-world impact remain challenging. Join this webinar to explore: Real-world applications for AI[…]
SEPTEMBER 15, 2021 By Joseph Zabinski, PhD, Senior Director of AI & Precision Medicine, OM1 As innovation in devices and diagnostics accelerates, research approaches and outcomes programs also need to advance to support these developments with high-quality evidence. At the same time, demonstrating the effectiveness of a device can be challenging because outcomes depend highly[…]
